Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.
复制标题

DOI:
10.1126/science.aad0095
复制
发表时间:
2015-10-09
期刊:
Science (New York, N.Y.)
影响因子:
--
通讯作者:
Garraway LA
Garraway LA
中科院分区:
其他
文献类型:
--
作者:
Van Allen EM;Miao D;Schilling B;Shukla SA;Blank C;Zimmer L;Sucker A;Hillen U;Foppen MHG;Goldinger SM;Utikal J;Hassel JC;Weide B;Kaehler KC;Loquai C;Mohr P;Gutzmer R;Dummer R;Gabriel S;Wu CJ;Schadendorf D;Garraway LA

文献摘要

参考文献

被引文献

相似文献

针对细胞毒性 T 淋巴细胞相关抗原 4 (CTLA-4) 的单克隆抗体(例如伊匹单抗)可通过抑制免疫检查点活性为转移性黑色素瘤患者带来可观的临床益处,但对这些疗法的反应的临床预测因子仍未完全表征。为了研究肿瘤特异性新抗原的作用以及肿瘤微环境的改变在伊匹单抗反应中的作用,我们分析了来自治疗前黑色素瘤肿瘤活检的整个外显子组和来自 110 名患者的匹配种系组织样本。对于其中 40 名患者,我们还获得并分析了治疗前肿瘤样本的转录组数据。免疫微环境中的总体突变负荷、新抗原负荷和溶细胞标记物的表达与临床获益显着相关。然而,没有复发的新抗原肽序列可以预测有反应的患者群体。因此,可能需要对大型患者群体进行详细的综合分子表征,以确定对免疫检查点抑制剂的反应和耐药性的稳健决定因素。
Monoclonal antibodies directed against cytotoxic T lymphocyte–associated antigen-4 (CTLA-4), such as ipilimumab, yield considerable clinical benefit for patients with metastatic melanoma by inhibiting immune checkpoint activity, but clinical predictors of response to these therapies remain incompletely characterized. To investigate the roles of tumor-specific neoantigens and alterations in the tumor microenvironment in the response to ipilimumab, we analyzed whole exomes from pretreatment melanoma tumor biopsies and matching germline tissue samples from 110 patients. For 40 of these patients, we also obtained and analyzed transcriptome data from the pretreatment tumor samples. Overall mutational load, neoantigen load, and expression of cytolytic markers in the immune microenvironment were significantly associated with clinical benefit. However, no recurrent neoantigen peptide sequences predicted responder patient populations. Thus, detailed integrated molecular characterization of large patient cohorts may be needed to identify robust determinants of response and resistance to immune checkpoint inhibitors.
DOI: 10.1056/nejmoa1003466
发表时间: 2010-08-19
期刊: The New England journal of medicine
影响因子: --
作者:
Hodi FS;O'Day SJ;McDermott DF;Weber RW;Sosman JA;Haanen JB;Gonzalez R;Robert C;Schadendorf D;Hassel JC;Akerley W;van den Eertwegh AJ;Lutzky J;Lorigan P;Vaubel JM;Linette GP;Hogg D;Ottensmeier CH;Lebbé C;Peschel C;Quirt I;Clark JI;Wolchok JD;Weber JS;Tian J;Yellin MJ;Nichol GM;Hoos A;Urba WJ
通讯作者: Urba WJ
DOI: 10.1016/j.ejca.2008.10.026
发表时间: 2009-01-01
影响因子: 8.4
作者:
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者: Verweij, J.
癌症免疫疗法。树突状细胞疫苗增加了黑色素瘤新抗原特异性T细胞的广度和多样性。
DOI: 10.1126/science.aaa3828
发表时间: 2015-05-15
期刊: Science (New York, N.Y.)
影响因子: --
作者:
Carreno BM;Magrini V;Becker-Hapak M;Kaabinejadian S;Hundal J;Petti AA;Ly A;Lie WR;Hildebrand WH;Mardis ER;Linette GP
通讯作者: Linette GP
DOI: 10.1016/j.cell.2014.12.033
发表时间: 2015-01-15
期刊: Cell
影响因子: 64.5
作者:
Rooney MS;Shukla SA;Wu CJ;Getz G;Hacohen N
通讯作者: Hacohen N
DOI: 10.1097/00002371-200401000-00007
发表时间: 2004-01-01
影响因子: 3.9
作者:
Hofbauer, GFL;Burkhart, A;Nestle, FO
通讯作者: Nestle, FO